COPD Severity Tied to Life Expectancy
A pooled US cohort study estimated years of life lost across airflow obstruction severity, including among adults who never smoked.
By
Kathryn Wighton
June 10, 2026
Clinical Scorecard: COPD Severity Tied to Life Expectancy
At a Glance
Category Detail
Condition Key Mechanisms Defined by prebronchodilator forced expiratory volume in 1 second to forced vital capacity ratio of less than 0.70. Target Population Care Setting
Key Highlights
COPD severity is associated with progressively lower modeled life expectancy. All-cause mortality rates increase with worsening GOLD stage. Estimated remaining life expectancy decreases from 21.5 years (no COPD) to 10.7 years (GOLD stage 4). Years of life lost increase with disease severity, from 0.7 years (GOLD stage 1) to 7.1 years (GOLD stage 4). Guideline-Based Recommendations
Diagnosis
COPD diagnosed based on prebronchodilator spirometry. Management
Consider severity classification using GOLD stages. Monitoring & Follow-up
Longitudinal follow-up for disease progression and spirometry updates. Risks
Increased mortality associated with worsening GOLD stage. Patient & Prescribing Data
Participants from the National Heart, Lung, and Blood Institute Pooled Cohorts Study.
Smoking status and comorbidities impact life expectancy.
Clinical Best Practices
Use GOLD staging for assessing COPD severity. Related Resources & Content
